ENDOTHERAPEUTICS Revenue and Competitors
Estimated Revenue & Valuation
- ENDOTHERAPEUTICS's estimated annual revenue is currently $23.6M per year.
- ENDOTHERAPEUTICS's estimated revenue per employee is $251,000
Employee Data
- ENDOTHERAPEUTICS has 94 Employees.
- ENDOTHERAPEUTICS grew their employee count by 8% last year.
ENDOTHERAPEUTICS's People
Name | Title | Email/Phone |
---|---|---|
1 | Product Specialist and Trainer | Reveal Email/Phone |
ENDOTHERAPEUTICS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $50.5M | 201 | 2% | N/A | N/A |
#2 | $127M | 506 | 22% | N/A | N/A |
#3 | $40.9M | 163 | 22% | N/A | N/A |
#4 | $230.2M | 917 | 20% | N/A | N/A |
#5 | $12.8M | 51 | -35% | N/A | N/A |
#6 | $50.8M | 162 | -13% | $5M | N/A |
#7 | $6.5M | 52 | -24% | $20.8M | N/A |
#8 | $27.9M | 111 | -2% | N/A | N/A |
#9 | $19.1M | 76 | 12% | N/A | N/A |
#10 | $272.3M | 1085 | 6% | N/A | N/A |
What Is ENDOTHERAPEUTICS?
Endotherapeutics is a leading Australian distributor of cutting-edge, niche surgical devices across various medical specialties. Established in 1999, the company has a reputation of successfully introducing innovative, new technologies to surgeons, healthcare professionals and medical facilities, while providing the highest level of customer service and clinical support.
keywords:N/AN/A
Total Funding
94
Number of Employees
$23.6M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ENDOTHERAPEUTICS News
Body Products, Carmonja, Changzhou Health Microport Medical, Dispomedica, Endo-Flex, ENDO-TECHNIK W. Griesat, Endo-Therapeutics, EndoChoice,...
Steris; CONMED; Avanos Medical Devices; Diversatek; Blue Endo; Carmonja; Changzhou Health Microport Medical Devices; EMED; Endo-Flex; Endo-...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $38.2M | 119 | 5% | N/A |
#2 | $59.2M | 163 | 3% | N/A |
#3 | $15M | 222 | 4% | N/A |
#4 | $38.4M | 241 | N/A | N/A |
#5 | $35M | 402 | 3% | N/A |